Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.63 |
| ▸ | NPC1 | O15118 | 8/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.63 |
| ▸ | HPGD | P15428 | 6/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | CASP1 | P29466 | 1/20 | 0.63 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | MGLL | Q99685 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14376088 | 0.91 | SMN1; SMN2 (0.61) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL7564852 | 0.87 | RAB9A (0.79) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL6347339 | 0.87 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL2033732 | 0.84 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL13387589 | 0.83 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL31079258 | 0.82 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL10192215 | 0.81 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL7564856 | 0.81 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL1699197 | 0.81 | SMN1; SMN2 (0.70) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL12411578 | 0.81 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1722796-A4 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007117289-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-18 | — | — | WO | disclosed |
| CN-101014343-A | Tetracyclic lactam derivatives and uses thereof | INOTEK PHARMACEUTICALS CORP (US) | 2007-08-08 | — | — | CN | disclosed |
| EP-1722796-A2 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | Inotek Pharmaceuticals Corporation (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050261288-A1 | Tetracyclic lactam derivatives and uses thereof | INOTEK PHARMACEUTICALS CORPORATION | 2005-11-24 | — | — | US | disclosed |
| WO-2005082079-A2 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261288-A1 | Tetracyclic lactam derivatives and uses thereof | PARK7, GLS, IAPP | RAB9A 1521/4885NPC1 4064/4885SMN1; SMN2 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.